Skip to main navigation menu Skip to main content Skip to site footer

Review article: Biomedical intelligence

Vol. 140 No. 3536 (2010)

Electronic cardiac medicine: present and future opportunities

  • Angelo Auricchio
  • Tiziano Moccetti
Cite this as:
Swiss Med Wkly. 2010;140:w13052


The second half of the 20th century witnessed a revolution in electronic medicine similar to that in pharmacology in the decades before. The advent of the implantable pacemaker, implantable cardioverter-defibrillators, cardiac resynchronisation therapies, insertable loop recorders and more, have improved diagnoses and reduced mortality and morbidity in millions of patients suffering from cardiac disease. The possibility to monitor patients continually without need for frequent office visits has the potential to reduce follow-up burden on physicians, facilitate increased use of home-based care and further improve the safety for patients. This review summarises the role of cardiac device therapies today and some of the developments which we can hope for in the nearest future.


  1. Rydén L, Schüller H, Larsson B. Biography of Arne Larsson.
  3. Vardas PE, Auricchio A, Blanc JJ, et al. for the Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy. Guidelines for cardiac pacing and cardiac resynchronization therapy. Europace. 2007;10:959–98.
  4. Sweeney MO, Hellkamp AS, Ellenbogen KA, et al., for Mode Selection Investigators. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932–7.
  5. Gillis AM, Pürerfellner H, Israel CW, et al. Reducing Unnecessary Right Ventricular Pacing with the Managed Ventricular Pacing Mode in Patients with Sinus Node Disease and AV Block Pacing Clin Electrophysiol. 2006;29:697–705.
  6. Sweeney MO, Bank AJ, Nsah E, et al. Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease. N Engl J Med. 2007;357:1000–8.
  7. Kalin R, Stanton MS. Current clinical issues for mri scanning of pacemaker and defibrillator patients. Pacing Clin Electrophysiol. 2005;28:326–8.
  8. Duru F, Luechinger R, Scheidegger MB, Luscher TF, Boesiger P, Candinas R. Pacing in magnetic resonance imaging environment: Clinical and technical considerations on compatibility. Eur Heart J. 2001;22:113–24.
  9. Levine GN, Gomes AS, Arai AE, et al. Safety of magnetic resonance imaging in patients with cardiovascular devices: An american heart association scientific statement from the committee on diagnostic and interventional cardiac catheterization, council on clinical cardiology, and the council on cardiovascular radiology and intervention: Endorsed by the American College of Cardiology Foundation, the North American Society for Cardiac Imaging, and the Society for Cardiovascular Magnetic Resonance. Circulation. 2007;116:2878–91.
  10. Luechinger R, Zeijlemaker VA, Pedersen EM, Mortensen P, Falk E, Duru F, et al. In vivo heating of pacemaker leads during magnetic resonance imaging. Eur Heart J. 2005;26:376–83.
  11. Roguin A, Schwitter J, Vahlhaus C, Lombardi M, Brugada J, Vardas P, et al. Magnetic resonance imaging in individuals with cardiovascularimplantable electronic devices. Europace. 2008;10:336–46.
  12. Rougin A, Schwitter J, Vahlhaus C, Lombardi M, Brugada J, Vardas P, et al. Magnetic resonance imaging in individuals with cardiovascular implantable electronic devices. A Position Paper from European Heart Rhythm Association and Working Group on Cardiovascular Magnetic Resonance of the European Society of Cardiology (EuroCMR). Europace. 2008;10:336–46.
  13. Dickstein K, Cohen-Solal A, Filippatos G, et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur J Heart Fail. 2008;10:933–89.
  14. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. on behalf of the investigators of the AVID, CASH and CIDS studies Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J. 2000;21:2071–8.
  15. Moss AJ, Zareba W, Hall WJ, et al., for the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–83.
  16. Bardy GH, Lee KL, Mark DB, et al. Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or implantable cardioverter-defirbrillator for congestive heart failure. N Engl J Med. 2005;352:225–37.
  17. Hohnloser SH, Kuck KH, Dorian P, Roberts RS, Hampton JR, Hatala R, et al.; DINAMIT Investigators. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481–8.
  18. Steinbeck G, Andresen D, Seidl K, Brachmann J, Hoffmann E, Wojciechowski D, et al.; IRIS Investigators. Defibrillator implantation early after myocardial infarction. N Engl J Med. 2009;361:1427–36.
  19. Goldenberg I, Moss AJ, McNitt S, Zareba W, Hall WJ, Andrews ML, et al., for the MADIT-II Investigators. Time dependence of defibrillator benefit after coronary revascularization in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol. 2006;47:1811–7.
  20. Schaer B, Kühne M, Koller MT, Sticherling C, Osswald S. Therapy with an implantable cardioverter defibrillator (ICD) in patients with coronary artery disease and dilated cardiomyopathy: benefits and disadvantages. Swiss Med Wkly. 2009;139:647–53.
  21. Goldenberg I, Vyas AK, Hall WJ, et al., for the MADIT-II Investigators. Risk stratification for primary implantation of a cardioverter defibrillator in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol. 2008;51:288–96.
  22. Gold MR, Ip JH, Costantini O, Poole JE, McNulty S, Mark DB, et al. Role of microvolt T-Wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-Wave Alternans Sudden Cardiac Death in Heart Failure Trial Substudy. Circulation. 2008;118:2022–8.
  23. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113:1424–33.
  24. Mozaffarian D, Anker SD, Anand I, Linker DT, Sullivan MD, Cleland JG, et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation. 2007;116:392–8.
  25. Wayne C, Levy WC, Lee KL, Hellkamp AS, Poole JE, Mozaffarian D, et al. Maximizing Survival Benefit With Primary Prevention Implantable Cardioverter-Defibrillator Therapy in a Heart Failure Population. Circulation. 2009;120:835–42.
  27. Wathen MS, DeGroot PJ, Sweeney MO. Prospective Randomized Multicenter Trial of Empirical Antitachycardia Pacing Versus Shocks for Spontaneous Rapid Ventricular Tachycardia in Patients With Implantable Cardioverter-Defibrillators. Circulation. 2004;110:2591–6.
  28. Wilkoff BL, Williamson BD, Stern RS. Strategic Programming of Detection and Therapy Parameters in Implantable Cardioverter-Defibrillators Reduces Shocks in Primary Prevention Patients. J Am Coll Cardiol. 2008;52:541–50.
  29. Bristow MR, Saxon LA, Boehmer J, et al.Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50.
  30. Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L. The effect of cardiac resynchronization on morbidity and mortality in heart failure. New Engl J Med. 2005;352:1539–49.
  31. Rivero-Ayerza M, Theuns DA, Garcia-Garcia HM, Boersma E, Simoons M, Jordaens LJ. Effects of cardiac resynchronisation therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. Eur Heart J. 2006;27:2682–8.
  32. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. N Engl J Med. 2003;348:1309–21.
  33. Cleland JG, Calvert MJ, Verboven Y, Freemantle N. Effects of cardiac resynchronization therapy on long-term quality of life: an analysis from the CArdiac Resynchronisation-Heart Failure (CARE-HF) study. Am Heart J. 2009;157:457–66.
  34. Ghio S, Freemantle N, Scelsi L, Serio A, Magrini G, Pasotti M, et al. Long-term left ventricular reverse remodelling with cardiac resynchronization therapy: results from the CARE-HF trial. Eur J Heart Fail. 2009;11:480–8.
  35. Daubert C, Gold MR, Abraham WT, Ghio S, Hassager C, Goode G, et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the european cohort of the reverse (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol. 2009;54:1837–46.
  36. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–38.
  37. Wikstrom G, Blomström-Lundqvist C, Andren B, et al. The effects of aetiology on outcome in patients treated with cardiac resynchronization therapy in the CARE-HF trial. Eur Heart J. 2009;30:782–8.
  38. Beshai JF, Grimm RA, Sherif DO, Nagueh F, Baker II JH, Beau, Greenberg SM Pires LA, Tchou PJ, for the RethinQ Study Investigators. Cardiac-Resynchronization Therapy in Heart Failure with Narrow QRS Complexes. N Engl J Med. 2007;357:2461–71.
  39. Chung ES, Leon AR, Tavazzi L, et al. Results of the Predictors of Response to CRT (PROSPECT) Trial. Circulation. 2008;117:2608–16.
  41. Barold SS, Herwerg B. Pacing in heart failure: how many leads and where? Heart. 2008;94:10–2.
  42. Rademakers LM, van Hunnik A, Lampert A, Kuiper M, Auricchio A, Echt DS, et al. Electrical and hemodynamic benefits of endocardial CRT with chronic infarction and LBBB. Heart Rhythm. 2009;6:S237.
  43. van Deursen C, van Geldrop I, van Hunnik A, Auricchio A, Echt D, Prinzen FW. Improved myocardial repolarization and left ventricular systolic and diastolic function during endocardial cardiac resynchronization therapy. Heart Rhythm. 2008;5:S188.
  44. van Gelder BM, Scheffer MG, Meijer A, Bracke FA. Transseptal endocardial left ventricular pacing: an alternative technique for coronary sinus lead placement in cardiac resynchronization therapy. Heart Rhythm. 2007;4:454–60.
  45. Van Veldhuisen DJ, Charlesworth A, Crijns HJGM, Lie KI, Hampton JR. Differences in drug treatment of chronic heart failure between European countries. Eur Heart J. 1999;20:666–72.
  46. Abraham WT, Young JB, Wheelan K, Johnson WB, Smith AL, Brinkman P, Chang Y. Comparison of sudden cardiac death in heart failure patients with cardiac resynchronization and defibrillator therapy (CRT-D) versus CRT alone (CRT-P). (Abstract). J Card Fail. 2008;14(Suppl. 1):S71.
  47. Stabile G, Solimene F, Bertaglia E, La Rocca V, Accogli M, Scaccia A, et al. Long-term outcomes of CRT-PM versus CRT-D recipients. Pacing Clin Electrophysiol. 2009;32:S141–5.
  48. Farwell DJ, Sulke AN. Does the use of a syncope diagnostic protocol improve the investigation and management of syncope? Heart. 2004;90:52–8.
  49. The Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Guidelines for the diagnosis and management of syncope (version 2009). Eur Heart J. 2009;30:2631–71.
  50. Brignole M, Vardas P, Hoffman E, et al. Indications for the use of diagnostic implantable and external ECG loop recorders. Europace. 2009;11:671–87.
  51. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al., Canadian Trial of Atrial Fibrillation Investigators Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med. 2000;342:913–20.
  52. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–33.
  53. Ziegler PD, Koehler JL, Mehra R. Comparison of continuous versus intermittent monitoring of atrial arrhythmias. Heart Rhythm. 2006;3(12):1445–52.
  54. Senatore G, Stabile G, Bertaglia E, Donnici G, De Simone A, Zoppo F, et al. Role of transtelephonic electrocardiographic monitoring in detecting short-term arrhythmia recurrences after radiofrequency ablation in patients with atrial fibrillation. J Am Coll Cardiol. 2005;45:873–6.
  55. Kottkamp H, Tanner H, Kobza R, Schirdewahn P, Dorszewski A, Gerds-Li JH, et al. Time courses and quantitative analysis of atrial fibrillation episode number and duration after circular plus linear left atrial lesions: trigger elimination or substrate modification: early or delayed cure? J Am Coll Cardiol. 2004;44:869–77.
  56. Sticherling C, Kühne M, Schaer B, Altmann D, Osswald S. Remote monitoring of cardiovascular implantable electronic devices. Prerequisite or luxury? Swiss Med Wkly. 2009;139:596–601.
  57. Swerdlow CD, Gunderson BD, Ousdigian KT, et al. Downloadable algorithm to reduce inappropriate shocks caused by fractures of implantable cardioverter-defibrillator leads, Circulation. 2008;118:2122–9.
  58. Wilkoff BL, Auricchio A, Brugada J, Cowie M, Ellenbogen KA, Gillis AM, et al. HRS/EHRA expert consensus on the monitoring of cardiovascular implantable electronic devices (CIEDs): description of techniques, indications, personnel, frequency and ethical considerations. Heart Rhythm. 2008;5:907–25.
  59. Yu CM, Wang L, Chau E, Chan RH, Kong S, Tang M, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. 2005;112:841e8.
  60. Catanzariti D, Lunati M, Landolina M, Zanotto G, Lonardi G, Iacopino S, et al. Monitoring intrathoracic impedance with an implantable defibrillator reduces hospitalizations in patients with heart failure. Pacing Clin Electrophysiol. 2009;32:363–70.
  61. Auricchio A. Is it time to start with device-based prognosticators? Europace. 2009;12:7–8.
  62. Singh JP, Rosenthal LS, Hranitzky PM, Berg KC, Mullin CM, Thackeray L, Kaplan A. Device diagnostics and long-term clinical outcome in patients receiving cardiac resynchronization therapy. Europace. 2009;11:1647–53.
  63. Husain S, Pamboukian SV, Tallaj JA, McGiffin DC, Bourge RC. Invasive monitoring in patients with heart failure. Curr Cardiol Rep. 2009;11:159–66.
  64. van Veldhuisen DJ, Maass AH, Priori SG, Stolt P, van Gelder IC, Dickstein K, Swedberg K. Implementation of device therapy (cardiac resynchronization therapy and implantable cardioverter defibrillator) for patients with heart failure in Europe: changes from 2004 to 2008. Eur J Heart Fail. 2009;11:1143–51.
  65. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, et al. The EuroHeart Failure Survey Programme – a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24:464–74.
  66. Cowie MR, Marshall D, Drummond M, Ferko N, Maschio M, Ekman M, et al. Lifetime cost effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace. 2009;11:716–26.
  67. Farwell DJ, Freemantle N, Sulke AN. Use of implantable loop recorders in the diagnosis and management of syncope. Eur Heart J. 2004;25:1257–63.
  68. Peytremann-Bridevaux I, Burnand B. Inventory and perspectives of chronic disease management programs in Switzerland: an exploratory survey. Int J Integr Care. 2009;9:e93
  69. Swedberg K, Cleland J, Cowie MR, Nieminen M, Priori SG, Tavazzi L, et al. Successful treatment of heart failure with devices requires collaboration. Eur J Heart Fail. 2008;10:1229–35.
  70. Regoli F, Auricchio A. The role of invasive mapping in the electrophysiology laboratory. Europace. 2009;11:v40-5.
  71. Leclercq C, Gadler F, Kranig W, Ellery S, Gras D, Lazarus A, et al. A randomized comparison of triple-site versus dual-site ventricular stimulation in patients with congestive heart failure. J Am Coll Cardiol. 2008;51:1455–62.
  72. Jørgensen HS, Nakayama H, Reith J, et al. Acute stroke with atrial brillation. The Copenhagen stroke study. Stroke. 1996;27:1765–9.
  73. Verma A, Wilkoff BL. Intravascular pacemaker and defibrillator lead extraction: a state-of-the-art review. Heart Rhythm. 2004;1:739–45.
  74. Peschar M, de Swart H, Michels KJ, Reneman RS, Prinzen FW. Left ventricular septal and apex pacing for optimal pump function in canine hearts. J Am Coll Cardiol. 2003;41:1218–26.
  75. Cohen MI, Bush DM, Vetter VL, Tanel RE, Wieand TS, Gaynor JW, Rhodes LA. Permanent epicardial pacing in pediatric patients: Seventeen years of experience and 1200 outpatient visits. Circulation. 2001;103:2585–90.
  76. Echt DS, Cowan MW, Riley RE, Brisken AF. Feasibility and safety of a novel technology for pacing without leads. Heart Rhythm. 2006;3:1202–6.
  77. Wieneke H, Konorza T, Erbel R, Kisker E. Leadless pacing of the heart using induction technology: a feasibility study. Pacing Clin Electrophysiol. 2009;32:177–83.
  78. Lee KL, Lau CP, Tse HF, Echt DS, Heaven D, Smith W, Hood M. First human demonstration of cardiac stimulation with transcutaneous ultrasound energy delivery: Implications for wireless pacing with implantable devices. J Am Coll Cardiol. 2007;50:877–83.
  79. Santini M, Cappato R, Andresen D et al. Current state of knowledge and experts’ perspective on the subcutaneous implantable cardioverter-defibrillator. J Interv Card Electrophysiol. 2009;25(1):83–8.
  80. Malliani A, Schwartz PJ, Zanchetti A. A sympathetic reflex elicited by experimental coronary occlusion. Am J Physiol. 1969;217:703–9.
  81. Schwartz PJ, Brown AM, Malliani A, Zanchetti A, editors. Neural Mechanisms in Cardiac Arrhythmias. New York: Raven Press, 1978:442.
  82. Schwartz PJ, Priori SG. Sympathetic nervous system and cardiac arrhythmias. In: Zipes DP, Jalife J, editors. Cardiac Electrophysiology: From Cell to Bedside. Third Edition. Philadelphia: WB Saunders, 2000:330–43.
  83. Schwartz PJ, Zipes DP. Autonomic modulation of cardiac arrhythmias. In: Zipes DP, Jalife J, editors. Cardiac Electrophysiology: From Cell to Bedside. Third Edition. Philadelphia: WB Saunders, 2000:300–14.
  84. Schwartz PJ, Vanoli E, Stramba-Badiale M, De Ferrari GM, Billman GE, Foreman RD. Autonomic mechanisms and sudden death. New insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction. Circulation. 1988;78:969–79.
  85. La Rovere MT, Pinna GD, Maestri R, et al. Prognostic implications of baroreflex sensitivity in heart failure patients in the beta-blocking era. J Am Coll Cardiol. 2009;53:193–9.
  86. Adamson PB, Smith AL, AbrahamWT, et al. InSync IIIModel 8042 and Attain OTW Lead Model 4193 clinical trial investigators. Continuous autonomic assessment in patients with symptomatic heart failure: prognostic value of heart rate variability measured by an implanted cardiac resynchronization device. Circulation. 2004;110:2389–94.
  87. Li M, Zheng C, Sato T, Kawada T, Sugimachi M, Sunagawa K. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation. 2004;109:120–4.
  88. Zhang Y, Popovic ZB, Bibevski S, et al. Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high rate pacing model. Circ Heart Fail 2009;2:642–9.
  89. Schwartz PJ, De Ferrari GM, Sanzo A, et al. Long term vagal stimulation in patients with advanced heart failure. First experience in man. Eur J Heart Fail. 2008;10:884–91.

Most read articles by the same author(s)